Affiliation:
1. Samarth Institute of Pharmacy, Belhe, Maharashtra, India
Abstract
The suitable Management of chronic pain COVID-19 pandemic is the most demanding process, particularly with developing evidence that COVID-19 Infection analogous to pain,muscle ache, extended neuropathic pain. This review provides the relavant management of chronic pain patients during the COVID-19 pandemic.Buprenorphine is a schedule third semisynthetic opioid analgesic show distinctive pharmacokinetic & pharmacodynamic properties, & involves vital role in chronic pain management in COVID-19.Transdermal formulation of buprenorphine provide controlled delivery for sustained analgesic effectiveness. It's matrix system permitts for slow release of baprenorphine & damage does not construct dose dumping i.e provides predictable serum buprenorphine level over a prolonged period. Also, Buprenorphine show minimal level of adverse effects compared to other opioids like morphine, fentanyl involves respiratory depression, addiction, euphoria, etc.& show good patient acceptance.